April 19, 2024 News by Lindsey Shapiro, PhD AAN 2024: Long-term data support early Kesimpta start in relapsing MS For people recently diagnosed with multiple sclerosis (MS), first-line treatment with Kesimpta (ofatumumab) was associated with a lower risk of disability progression over starting it after about 2.5 years of using Aubagio (teriflunomide). That’s according to six years of data spanning the ASCLEPIOS I (NCT02792218) and…
April 18, 2024 Columns by Benjamin Hofmeister Learning how to write a ‘SOAP’ note feels different after an MS diagnosis Training to become a U.S. Army Special Forces medic included all the things you might expect, as well as some you might not. Although trauma was our primary focus, we also had to be well versed in routine medicine and have a working knowledge of other aspects of healthcare.
April 18, 2024 News by Marisa Wexler, MS AAN 2024: Sustained myelin, nerve cell gains with long-term CNM-Au8 Long-term treatment with Clene Nanomedicine‘s experimental oral therapy CNM-Au8 led to signs of sustained improvements in nerve and myelin health for people with relapsing-remitting multiple sclerosis (RRMS) over three years, according to new data from the VISIONARY-MS clinical trial. The findings continue to support Clene’s plans to…
April 18, 2024 News by Lindsey Shapiro, PhD AAN 2024: Ocrevus benefits Black, Hispanic patients same as whites Ocrevus (ocrelizumab) had similar benefits in Black and Hispanic multiple sclerosis (MS) patients as earlier clinical trials with white patients did, one-year data from the CHIMES clinical trial indicates. About half of the CHIMES participants achieved no evidence of disease activity, or NEDA, which is defined as the…